“The EU regulatory environment needs to be optimized in order to deal with the growing demand for generic and biosimilar medicines. These medicines, which are now front-line treatments for a whole range of chronic diseases and account for nearly 50% of all medicines dispensed to European patients are the key to healthcare sustainability in the EU and the European regulatory system needs to reflect this reality.”
This was the key message of Greg Perry, director general of the European Generic medicines Association (EGA), as he presented the association’s Vision 2015 at the EGA’s 10th Regulatory and Scientific Affairs Conference, held in London, UK, yesterday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze